Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (20800)	8/10/2006 6:42:18 PM
From: DewDiligence_on_SI	Respond to of 52153

Lucentis is a monthly shot in the eye with a very sharp stick; the Briefing clip said RNAI's tx was a single dose. If that's the case both Retinal Specialists and patients will opt for shot, all else equal. Patients will need repeat dosing to maintain an improvement in vision: investorshub.com This is a good start, but there is much work left to do. Open-label AMD trials should be looked at with skepticism. An improvement in visual acuity relative to baseline could result from such a seemingly minor variation as a patient leaning forward in the chair while reading the eye chart. As Tuck mentioned, GENR is a case in point. GENR’s early, open-label data were similar to (actually slightly better than) RNAI’s, yet GENR has been unable to replicate the early data in any randomized trials to date.